Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-02T21:01:35.686Z.
Consensus retrieved: 2026-10-02T16:28:45.795Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-02T21:01:35.686Z.
Quote observation: 2026-10-02T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 054a65786064a73545931b308e74131b250e2c5f6c2462854f5738f681d07736
Forward PE Ratio (N/A) = Dated Quote Price ($410.35) / Consensus Forward EPS ($-1.39)
FORWARD PE RATIO
N/A
Natera, Inc.
Market Cap
$58.77B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Natera, Inc. (NTRA) | $58.77B | N/A |
| Cencora, Inc. (COR)vs › | $60.13B | 15.59 |
| Boston Scientific Corporation (BSX)vs › | $63.32B | 13.02 |
| Cardinal Health, Inc. (CAH)vs › | $53.47B | 18.20 |
| Edwards Lifesciences Corporation (EW)vs › | $49.03B | 28.37 |
| Becton, Dickinson and Company (BDX)vs › | $48.72B | 13.35 |
| Agilent Technologies, Inc. (A)vs › | $47.38B | 27.06 |
| Humana Inc. (HUM)vs › | $46.63B | 42.41 |
| Cigna Corporation (CI)vs › | $71.48B | 8.87 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $46.04B | 20.04 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $410.35, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.39 | $-1.62 – $-0.80 | 13 | n/m |
| 2027-12-31 | $-0.17 | $-1.34 – $0.84 | 13 | n/m |
| 2028-12-31 | $1.57 | $-0.40 – $4.42 | 17 | 261.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
